Singapore 25 April 2025 – PSI CRO AG, a global Swiss-based clinical research organization (CRO), is pleased to announce the opening of its new office in Singapore. Located in the prestigious Singapore Science Park (2 Science Park Drive, Ascent, #01-08), a premier center for research and innovation, the new facility marks a significant milestone in PSI’s strategic expansion across the Asia-Pacific region.
The move strengthens PSI’s operational capabilities to support clinical trial sponsors with enhanced site engagement, faster feasibility assessments, and more agile project oversight. The space features a private office and modern meeting rooms within a dynamic coworking environment, enabling PSI to foster closer collaboration with clients, investigators, and strategic partners.
“This new location reinforces our commitment to delivering high-quality, on-time clinical trials for sponsors seeking to expand into or accelerate trials across Asia-Pacific,” said Barrie Koh, Head of Asia Pacific, at PSI. “It allows us to be even closer to key sites, investigators, and regulatory bodies, ensuring seamless execution and responsiveness for our global partners.”
The opening celebration included PSI leadership highlighting the organization’s ongoing investment in regional expertise and operational excellence. In keeping with local tradition, the team marked the occasion with a pineapple rolling ceremony, symbolizing prosperity and good fortune for new beginnings.
For more information about PSI’s global capabilities and services, please visit psi-cro.com.
About PSI
PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is on-time delivery of clinical trials. This metric remained above 90% in 2024.
The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.
In 2025, PSI is celebrating its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,000 people across 56 countries as of December 31, 2024. Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.
For more information, visit www.psi-cro.com.
For Media Inquiries
Paul Mirek
